Beige mouse model for Mycobacterium avium complex disease

s of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 60. Ji, B. , N. Lounis, C. Truffot-Pernot, and J. H. Grosset. 1992. Bactericidal activities of multidrug regimens againstM. avium in beige mice, abstr. 1668, p. 389. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 61. Ji, B. , N. Lounis, C. Truffot-Pernot, and J. H. Grosset. 1992. Selection of resistant mutant of Mycobacterium avium in beige mice by clarithromycin monotherapy. Antimicrob. Agents Chemother. 36:2839–2840. 62. Ji, B. , N. Lounis, C. Truffot-Pernot, and J. H. Grosset. 1994. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in beige mouse model. Antimicrob. Agents Chemother. 38:2521–2529. 63. Kailasam, S. , D. L. Wise, and P. R. J. Gangadharam. 1994. Bioavailability and chemotherapeutic activity of clofazimine in vivo for prolonged periods following a single implant of a biodegradable polymer. J. Antimicrob. Chemother. 33:273–279. 64. Kanyok, T. P., M. V. Reddy, J. Chinnaswamy, L. H. Danziger, and P. R. J. Gangadharam. 1994. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob. Agents Chemother. 38:170–173. 65. Kleeberg, H. H. , and E. E. Nel. 1973. Occurrence of environmental atypical mycobacteria in South Africa. Ann. Soc. Biol. Med. Trop. 1973:405–417. 66. Klemens, S. P., and M. H. Cynamon. 1991. In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob. Agents Chemother. 35:2026–2030. 67. Klemens, S. P., and M. H. Cynamon. 1992. Activity of rifapentine against Mycobacterium avium infection in beige mice. J. Antimicrob. Chemother. 29:555–561. 68. Klemens, S. P., and M. H. Cynamon. 1994. Intermittent azithromycin for treatment of Mycobacterium avium infection in beige mice. Antimicrob. Agents Chemother. 38:1721–1725. 69. Klemens, S. P., H. Cynamon, C. E. Swenson, and R. S. Ginsberg. 1990. Liposome encapsulated gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. 34:967–970. 70. Klemens, S. P., M. S. Destefano, and M. H. Cynamon. 1991. Clarithromycin in combination with other agents againstM. avium complex (MAC) in beige mice. AIDS Weekly, p. 22. 71. Klemens, S. P., M. S. DeStefano, and M. H. Cynamon. 1992. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob. Agents Chemother. 36:2413–2417. 72. Kolonoski, P. T. , M. Wu, C. B. Inderlied, and L. S. Young. 1992. Azithromycin (AZM), ethambutol (EMB) and sparfloxacin (SP) for disseminated Mycobacterium avium complex (MAC) infection in C57 beige mice, abstr. 1666, p. 388. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. 73. Krause, M. W. and A. Schaffner. 1989. Comparison of immunosuppressive effects of cyclosporine A in a murine model of systemic candidiasis and of localized thrushlike lesions. Infect. Immun. 57:3472–3478. 74. Kuze, F. 1984. Experimental chemotherapy of chronic Mycobacterium avium intracellulare infection of mice. Am Rev. Respir. Dis. 129:453–459. 75. Kuze, F. , R. Amitani, N. Sakuran, and S. Togawa. 1986. Murine models of Mycobacterium avium complex infection. In Proceedings of the Joint Meeting of the 5th Annual Conference of European Society of Pneumonology and 21st Annual Congress of European Society for Clinical Physiology. 76. Kuze, F. , T. Yamamoto, R. Amitani, and K. Suzuki. 1991. In vivo activities of new rifamycin derivatives against mycobacteria. Kekkaku 66:7–12. 77. Lane, P. W. , and E. D. Murphy. 1972. Susceptibility to spontaneous pneumonitis in an inbred strain of beige and satin mice. Genetics 72:451–460. 78. Laughon, B. E. , H. S. Allaudeen, J. M. Becker, W. L. Current, J. Feinberg, J. K. Frenkel, R. Hafner, W. T. Hughes, C. A. Laughlin, J. D. Meyers, L. K. Schrager, and L. S. Young. 1991. Summary of the workshop on future directions in discovery and development of therapeutic agents for opportunistic infections associated with AIDS. J. Infect. Dis. 164:244–251. 79. Lazard, T. , C. Perronne, J. Grosset, J. L. Vilde, and J. J. Pocidalo. 1993. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. Antimicrob. Agents Chemother. 37:1690–1692. 80. Le Conte, P., F. Le Gallou, G. Potel, L. Struillou, D. Baron, and H. B. Drugeon. 1994. Pharmacokinetics, toxicity and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. Antimicrob. Agents Chemother. 38:2695–2701. 81. Meissner, P. S. , and J. O. Falkinham III. 1986. Plasmid DNA profiles as epidemiological markers for clinical and environmental isolates of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium scrofulaceum. J. Infect. Dis. 153:325–331. 82. Myers-Davit, B. , L. Gosey, L. Iacono-Connors, and S. H. Ohanian. 1995. Toxicokinetic studies of rifampin in beige mice. Proceedings of Annual Meeting of Society for Toxicology. Society for Toxicology, Reston, Va. 83. Pflumino, F. , P. P. Fonteneaw, C. Gaverianx, S. Cammisuli, and F. Loor. 1989. The C57BL/6 nude ‘‘beige’’ mouse, a model of combined T cell and NK effective cell immunodeficiency. Cell. Immunol. 120:218–219. 84. Pierce, C. H. , R. J. Dubos, and G. Middlebrook. 1947. Infection of mice with mammalian tubercle bacilli grown in Tween-albumin medium. J. Exp.